Rice Bran Supplement Containing A Functional Substance, the Novel Peptide Leu-Arg-Ala, has Anti-Hypertensive Effects: A Double-Blind, Randomized, Placebo-Controlled Study.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

The purpose of this study was to assess the anti-hypertensive effects of a rice bran supplement containing PRB in individuals with high-normal blood pressure (systolic blood pressure (SBP): 130⁻139 mmHg and/or diastolic blood pressure (DBP): 85⁻89 mmHg) or grade 1 hypertension (SBP: 140⁻159 mmHg and/or DBP: 90⁻99 mmHg).

Why It Was Studied

The anti-hypertensive effect of processed rice bran (PRB) was recently reported, for which the novel peptide Leu-Arg-Ala (LRA) was identified as the functional substance.

Participants were randomly allocated to the placebo group (n = 50) or the test group (n = 50).

Who Took Part

The study group was 87 participants.

The age groups tagged for this paper are middle-aged adults, both men and women.

One hundred individuals with high-normal blood pressure or grade 1 hypertension were recruited to participate in this double-blind, randomized, placebo-controlled study.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

What Was Measured

Participants were randomly allocated to the placebo group (n = 50) or the test group (n = 50).

PubMed files the paper under topics including Blood Pressure, Dietary Supplements, Heart Rate, Hypertension, Oryza, Peptides and Plant Proteins.

Author keywords: anti-hypertensive effect, double-blind randomized placebo-controlled study, high-normal blood pressure, novel peptide and rice bran.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 87 participants.

The publication is from 2019 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.